Bayer(US:BAYRY) Zheng Quan Shi Bao Wang·2025-09-08 12:06Core Insights - Bayer has launched the Bayer Co.Lab AdVenture, a global venture capital alliance linked to its life sciences co-creation platform, Bayer Co.Lab [1] - The Bayer Co.Lab in Shanghai will officially open in September 2024, focusing on cutting-edge innovations in cell and gene therapy, oncology, and new technology platforms [1] - China is transitioning from being an "innovator follower" to a "source of innovation," with approximately 30% of global research pipelines currently under development in the country [1] Company Developments - The first batch of partners for the Bayer Co.Lab AdVenture includes Shunwei Capital, Legend Capital, IDG Capital, and Kangjun Capital, which will provide industry insights and specialized investment opportunities [2] - Seven biotech startups have now joined Bayer Co.Lab, covering a range of innovative technologies including small molecules, nucleic acid drugs, cyclic peptide drugs, antibody platforms, gene editing, and AI drug discovery [2] - Bayer aims to deepen collaboration with local innovation forces to drive breakthrough innovations that address global health challenges, benefiting patients in China and worldwide [2]